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Biological assays 
 
In vitro antileishmanial activity – assay on promastigotes. Promastigote stage of L. infantum 
strain MHOM/TN/80/IPT1 and L. tropica (MHOM/IT/2012/ISS3130) were cultured in 
Schneider’s Drosophila medium (Lonza) supplemented with 10% heat-inactivated fetal calf 
serum (HyClone) at 22 °C. The complete medium used for antileishmanial activity assay was 
RPMI (EuroClone) supplemented with 10% heat-inactivated fetal calf serum (EuroClone), 20 
mM Hepes, and 2 mM L-glutamine. To estimate the 50 % inhibitory concentration (IC50), the 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) method was used with 
modifications.1 Compounds were dissolved in DMSO and then diluted with medium to achieve 
the required concentrations. Drugs were placed in 96 wells round-bottom microplates and seven 
serial dilutions made. Amphotericin B was used as the reference anti-Leishmania drug. Parasites 
were diluted in complete medium to 5×106 parasites/mL and 100 μL of the suspension was 
seeded into the plates, incubated at 22 °C for 72 h and then 20 µL of MTT solution (5 mg/mL) 
was added into each well for 3 h. The plates were then centrifuged, the supernatants discarded 
and the resulting pellets dissolved in 100 µL of lysing buffer consisting of 20% (w/v) of a 
solution of SDS (Sigma), 40% of N,N-dimethylformamide (Merck) in H2O. The absorbance was 
measured spectrophotometrically at a test wavelength of 550 nm and a reference wavelength of 
650 nm. The results are expressed as IC50 which is the dose of compound necessary to inhibit 
parasite growth by 50%; each IC50 value is the mean ± standard deviation of separate 
experiments performed in duplicate. 
 
In vitro intracellular amastigote susceptibility assays. THP-1 cells (human acute monocytic 
leukemia cell line) were maintained in RPMI supplemented with 10% FBS (EuroClone), 50 M 
2-mercaptoethanol, 20 mM Hepes, 2 mM glutamine, at 37 °C in 5% CO2. For Leishmania 
infections, THP-1 cells were plated at 5×105 cells/mL in 16-chamber Lab-Tek culture slides 
(Nunc) and treated with 0.1 M phorbol myristate acetate (PMA, Sigma) for 48 h to achieve 
differentiation into macrophages. Cells were washed and infected with metacyclic L. infantum 
promastigotes at a macrophage/promastigote ratio of 1/10 for 24 h. Cell monolayers were then 
washed and incubated in the presence of test compounds for 72 h. Slides were fixed with 
methanol and stained with Giemsa. The results are expressed as the percentage of infected 
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macrophages in treated and non-treated cells determined by light microscopyand as IC50 which is 
the dose of compound necessary to inhibit parasite growth by 50%; each IC50 value is the mean ± 
standard deviation of separate experiments performed in duplicate.  
 
Cytotoxicity against differentiated THP-1 cells. THP-1 cells were plated at 5×105 cells/mL in 
96 wells flat bottom microplates and treated with 0.1 M PMA for 48 h to achieve differentiation 
into macrophages. Cells were then treated for 72 hours with serial dilutions of test compounds 
and cell viability evaluated using the MTT assay already described.2 The results are expressed as 
IC50, which is the dose of compound necessary to inhibit cell growth by 50%.  
 
Nitric oxide and ROS production. Immortalized mouse C57Bl/6 bone marrow derived 
macrophages (BMDM) were generated as described3 and maintained in Dulbecco’s minimal 
essential medium, DMEM (Euroclone, Italy) supplemented with 10% FBS (EuroClone), 2 mM 
L-glutamine, 20 mM HEPES at 37 °C in 5% CO2. For NO and ROS production, BMDM were 
seeded (96-well plates; 1×105 cells/well) and incubated overnight. Cells were then primed with 
50 U/ml of Interferon-gamma (IFN-γ) for 2h, and treated for 24 hours with different 
concentrations of 15 (5, 2.5, 1.25 µM) or 10 (2.5, 1.25, 0.625 µM). LPS (100 ng/mL) was used 
as positive control. Cell viability was determined by MTT assay. Nitric oxide production was 
measured in cell supernatants by Griess reaction.4 The Griess reagents consisted in a mixture of 
equal parts of Reagent A (1% [w/v] sulphanilamide), and Reagent B (0.1% [w/v] 
naphthylethylenediamine dihydrochloride, and 2.5% [w/v] phosphoric acid). Fifty microliters of 
supernatants were mixed with an equal volume of Griess mixture and the nitrite levels were 
quantified by extrapolation from NaNO2 standard curve. Absorbance was measured at 540 nm 
using a microplate reader (Synergy 4 microplate reader, Biotek, GE). ROS production was 
measured using the H2DCFDA dye. After treatment of BMDM (as described above), the medium 
was discarded, the macrophages were washed with PBS, and incubated with H2DCFDA (20µM 
in PBS) for 30 min in the dark at 37 °C in 5% CO2. The supernatants were transferred into a flat-
bottom black plate and fluorescence was measured spectrofluorometrically using an excitation 
wavelength of 485 nm and an emission wavelength of 528 nm by a Synergy 4, Biotek®. 
Statistical analyses were performed with GraphPad Prism 5 software by using 1-way ANOVA 
test followed by Bonferroni’s post hoc test.  
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Tolerability studies in mice. Groups of four or five healthy female C57Bl/6 mice were treated 
per os (p.o.) or subcutaneous (s.c.) in a single dose with aminoquinolines suspended in 0.5% 
hydroxyethylcellulose-0.1% Tween 80 previously dissolved in DMSO (for p.o.) or dissolved in 
sunflower oil (for s.c.). Individual mouse behavior and appearance was monitored two times a 
day for 30 days. Compounds proved to be tolerable in mice if all mice survived 30 days after 
administration and showed normal appearance and behavior. The study followed the 
International Guiding Principles for biomedical research involving animals, and was reviewed by 
a local Ethics Committee and approved by the Veterinary Directorate at the Ministry of 
Agriculture and Environmental Protection of Serbia (decision no. 323-07-02444/2014-05/1). 
 
Antileishmanial activity in vivo. A standard protocol using a short-term infection of Balb/c 
mice with Leishmania infantum was employed.5 Briefly, a semi-purified suspension of 2×106 
Leishmania infantum amastigotes (WHO reference strain: MHOM/TN/1980/IPT-1), was 
inoculated via the tail vein in groups of Balb/c mice weighing 18-20 g.  On day 7 after infection 
the increase in parasite load was monitored by killing one animal from the control group. Liver 
was weighed, from which imprints were made and parasites counted against 500 liver cell nuclei. 
Their numbers were expressed as arbitrary units, i.e. the number of parasites per liver cell 
nucleus multiplied by the weight of the organ in mg. The compounds were dissolved and 
administered per os (15 in 0.1%Tween/0.5%HEC in water; 10 in water) or s.c. (15 in sunflower 
oil; 10 in water), for 4 or 5 consecutive days from day 9 after infection. A group of mice was left 
untreated and served as control. On days 13 or 14, the parasite load of killed mice was assessed 
as described above, and the mean parasite count of each treated group was expressed as a 
percentage of the mean parasite count of the control group. The study followed the International 
Guiding Principles for biomedical research involving animals (European Directive 2010/63/UE), 
and it was reviewed by a local Ethics Committee. The study was approved by the Directorate of 
Animal Health and Veterinary Drugs at the Ministry of Health of Italy (authorization no. 
120/2015-PR).   
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Chemistry. Melting points were determined on a Boetius PMHK apparatus and were not 
corrected. IR spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal 
spectrophotometer. 1H and 13C NMR spectra were recorded on a Varian Gemini-200 
spectrometer (at 200 and 50 MHz, respectively), and a Bruker Ultrashield Advance III 
spectrometer (at 500 and 125 MHz, respectively) in the indicated solvent (vide infra) using TMS 
as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants 
(J) in Hz. ESI–MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent 
Technologies 1200 Series instrument equipped with Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 
1.8 μm) column and DAD detector (190-450 nm) in combination with a 6210 Time-of-Flight 
LC/MS instrument in positive and negative ion mode. The samples were dissolved in MeOH 
(HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 
°C; drying gas 12 L min-1; nebulizer pressure 45 psig; fragmentator voltage: 70 V. Mass spectral 
analyses were done using electrospray ionization in positive ion mode on a Surveyor separations 
module coupled to a ThermoFinnigan TSQ AM triple quadrupole mass spectrometer. Gas 
chromatography tandem mass spectrometry (GC-MS) analyses were performed on an Agilent 
7890A GC (Agilent) system equipped with a 5975C inert XL EI/CI MSD and a flame ionization 
detector (FID) connected by capillary flow technology through a 2-way splitter with make-up 
gas. An HP-5 MS capillary column (Agilent Technologies, 25 mm i.d., 30 m length, 0.25 μm 
film thickness) was used. The flash chromatography was performed on Biotage SP1 system 
equipped with UV detector and FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with 
KP-SIL (40 – 63 µm, pore diameter 60 Å), KP-C18-HS (40 – 63 µm, pore diameter 90 Å) or KP-
NH (40 – 63 µm, pore diameter 100 Å) as an adsorbent. Elemental analyses were realized with 
an Elemental Vario EL III microanalyser. All tested compounds were fully characterized and 
their purity was >95% (as determined by HPLC).  
 
Methods for HPLC purity analyses 
Compounds were analyzed for purity (HPLC) using a Agilent 1200 HPLC system equipped with 
Quat Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 ( G1316A) and Detector 1260 
DAD VL+ (G1315C). HPLC analysis was performed in two diverse systems for each compound. 
Method A: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
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and methanol (B). The analysis were performed at the UV max of the compounds (at 254 nm for 
compounds 4, 6 and 21, 270 nm for compounds 3 and 5, 290 nm for 22 and 23 and 330 nm for 
compounds 1, 2, 10, 24 and 25) to maximize selectivity. Compounds were dissolved in 
methanol, final concentrations were ~1 mg/mL. Flow rate was 0.2 mL/min. 
Compounds 1-6 and 21 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 
5%A, 6-11 min 5%A, 11-14 min 5%A→ 95%A, 14-20 min 95%A. 
Compound 10 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-
16 min 5%A, 16-18 min 5%A→ 95%A, 18-20 min 95%A. 
Compound 22 was eluted using gradient protocol: 0-1 min 95%A, 1-3 min 95%A→ 5%A, 3-7 
min 5%A, 7-8 min 5%A→ 95%A, 8-9 min 95%A.   
Compound 23 was eluted using gradient protocol: 0-2 min 95%A, 2-4 min 95%A→ 5%A, 4-10 
min 5%A, 10-11 min 5%A→ 95%A, 11-12 min 95%A.  
Compounds 24 and 25 were eluted using gradient protocol: 0-1 min 95%A, 1-2 min 95%A→ 
5%A, 2-10 min 5%A, 10-11 min 5%A→ 95%A, 11-12 min 95%A.  
Method B: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 254 nm 
for compound 21, 270 nm for compounds 3, 4 and 6 and 330 nm for compounds 1, 2, 5, 10, 24 
and 25) to maximize selectivity. Compounds were dissolved in methanol, final concentrations 
were ~1 mg/mL. Flow rate was 0.2 mL/min. 
Compounds 1-6 and 21 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 
5%A, 6-11 min 5%A, 11-14 min 5%A→ 95%A, 14-20 min 95%A.  
Compound 10 was eluted using gradient protocol: 0-1.5 min 95%A, 1.5-5 min 95%A→ 5%A, 5-
16 min 5%A, 16-18 min 5%A→ 95%A, 18-20 min 95%A.  
Compound 24 was eluted using gradient protocol: 0-1 min 95%A, 1-3 min 95%A→ 5%A, 3-8 
min 5%A, 8-10 min 5%A→ 95%A, 10-11 min 95%A.  
Compound 25 was eluted using gradient protocol: 0-1 min 95%A, 1-3 min 95%A→ 5%A, 3-8 
min 5%A, 8-10 min 5%A→ 95%A. 
Method C: Zorbax Eclipse Plus C18 4.6 x 150mm, 1.8µ, S.N. USWKY01594 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and methanol (B). The analysis were performed at the UV max of the compounds (at 330 nm for 
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compound 15) to maximize selectivity. Compounds were dissolved in methanol, final 
concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min.  
Compound 15 was eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 5%A, 6-11 
min 5%A, 11-14 min 5%A→ 95%A, 14-16 min 95%A. 
Method D: Poroshell 120 EC-C18, 4.6 x 50mm, 2.7µ, S.N. USCFU07797 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 254 nm 
for compound 15) to maximize selectivity. Compounds were dissolved in methanol, final 
concentrations were ~1 mg/mL. Flow rate was 0.5 mL/min. 
Compound 15 was eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95%A→ 5%A, 6-11 
min 5%A, 11-13 min 5%A→ 95%A, 13-17 min 95%A. 
Method E: Poroshell 120 EC-C18, 4.6 x 50mm, 2.7μ, S.N. USCFU07797 was used as the 
stationary phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) 
and methanol (B). The analysis was performed at the UV max of the compounds (290 nm for 
compounds 22 and 23) to maximize selectivity. Compound was dissolved in methanol, final 
concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. 
Compounds 22 and 23 were eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95%A→ 
5%A, 1.5-6min 5%A, 6-7 min 5%A→ 95%A, 7-8 min 95%A. 
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Synthetic procedures 
 
Procedure A: General procedure for nucleophilic substitution.6 
A solution of 317 (1 equiv) in DCM was cooled to 0 ºC, followed by addition of amine (1.5 
equiv) and Et3N (1.5 equiv). The reaction mixture was stirred on ice bath for 15 minutes, 
warmed to r.t. and after another 15 minutes heated to reflux for 1h. The mixture was transferred 
to a separation funnel, water was added and desired product extracted with DCM. Combined 
organic layers were dried over anh. MgSO4 and the solvent was removed under reduced pressure. 
Procedure B: General procedure for reduction using tin(II)-chloride.  
Using slightly modified procedure from literature7, a mixture of 3-nitroquinoline derivative 
(1 equiv) and SnCl2 (5 equiv) in EtOH was stirred at r.t. under Ar atmosphere for 2 h. Solvent 
was removed under reduced pressure, followed by addition of sat. NaHCO3. Crude product was 
extracted several times with EtOAc. Combined extracts were washed with brine, dried over anh. 
MgSO4 and the solvent was evaporated under reduced pressure. 
Procedure C: General procedure for Boc-protecting group removal with TFA.  
A solution of amine in TFA/DCM mixture (v:v; 1:10) was stirred at r.t. overnight. Solvents were 
evaporated under reduced pressure and the residue was dissolved in DCM. The organic layer was 
washed several times with 2.5M NaOH and finally with water, dried over anh. MgSO4 and the 
solvent was removed under reduced pressure. 
Procedure D: General procedure for reductive amination. 
Amine (1.2-1.5 equiv) and appropriate aldehyde (1 equiv) were dissolved in MeOH/DCM 
mixture (v:v; 2:1), glac. AcOH (1.5 equiv) was added, and the mixture was stirred under Ar 
atmosphere at r.t. After 3 h, NaBH4 (6 equiv) was added, and stirring was continued for another 
18 h. Solvent was removed under reduced pressure, and the residue was dissolved in DCM. The 
organic layer was washed with 2M aqueous NH3 and extracted with DCM. The combined 
organic layers were washed with brine and dried over anh. Na2SO4. Finally, the solvent was 
evaporeted under reduced pressure. 
Procedure E: General procedure for Buchwald-Hartwig amination8 
A suspension of Pd(OAc)2 (4.00 mol %) and SPhos (8.00 mol %) in dioxane was purged with Ar 
and stirred at r.t. After three minutes, solution of 45 (1 equiv) in dioxane, an appropriate amine 
(1.5 equiv) and K3PO4 (2.5 equiv) were added. The mixture was heated at 85 °C for 24 h in a 
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sealed tube. After filtration the crude product was purified using column chromatography (dry 
flash, SiO2, eluent EtOAc/MeOH and flash, Biotage SP1, NH column, elunet EtOAc/MeOH). 
 
N-(7-chloroquinolin-4-yl)propane-1,3-diamine (AQ3) and N-(quinolin-4-yl)butane-1,4-diamine 
(AQ8) were prepared according to known procedures. 
 
tert-Butyl (3-aminopropyl)carbamate (S1). 
According to the procedure described in literature9, a solution of Boc2O 
(518.2 mg, 2.374 mmol) in DCM (10 mL) was added dropwise to a solution 
of propane-1,3-diamine (1 mL, 12 mmol) in DCM (40 mL). Reaction mixture was stirred at r.t. 
for 24h. Thereafter the solvent was removed under reduced pressure and the product was purified 
using column chromatography (dry-flash, SiO2, eluent DCM/MeOH gradient 6/4 → MeOH). 
Final product S1 was obtained as a yellowish oil (228.0 mg, 55%). IR (ATR): 3350m, 2976s, 
2934m, 1692s, 1525s, 1391m, 1366m, 1277m, 1252m, 1173s, 1060w, 871w, 780w cm-1. 1H 
NMR (500 MHz, CDCl3, δ): 4.95 (bs, H-N), 3.24-3.20 (m, 2H, NH2CH2CH2CH2-), 2.79 (t, 2H, J 
= 6.7, NH2CH2-), 1.98 (bs, -NH2), 1.66-1.61 (m, 2H, NH2CH2CH2-), 1.44 (s, 9H, -
NHCOOC(CH3)3). 13C NMR (125 MHz, CDCl3, δ): 156.19, 79.11, 39.47, 38.30, 33.01, 28.39. 
HRMS: m/z 175.14407 corresponds to molecular formula C8H18N4O2H+ (error in ppm -0.20). 
 
7-Chloroquinolin-4-amine (S2).10 
To the solution of 4,7-dichloroquinoline (676 mg, 3.41 mmol) in phenol (3.2 g, 
34 mmol) stirring in two-necked flask at 110 °C, ammonium-carbonate (1.64 g, 
17.1 mmol) was added in portions in a manner determined by intensity of foam 
developing in the flask. When addition was completed, the mixture was stirred at 165 °C for 3h. 
After cooling to r.t. diethylether was added. The solution was washed with 10% aqueous NaOH, 
extracted with diethylether and dried over anh. Na2SO4. The product was purified using column 
chromatography (dry-flash, SiO2, eluent DCM /MeOH). Final product S2 was obtained as white 
solid (602 mg, 99%). M.p. = 137 – 139 ºC. IR (KBr): 3459s, 3358s, 3241s, 2460m, 1698m, 
1639s, 1612s, 1576s, 1508s, 1445s, 1378m, 1327m, 1284m, 1201m, 1130m, 1078m, 910m, 
879m, 855m, 839m, 813m, 761m, 675w, 644w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.26 (d, J 
= 5.5, H-C(2)), 8.05 (d, J = 8.9, H-C(5), 7.77 (d, J = 2.1, H-C(8)), 7.37 (dd, J1 = 9.0, J2 = 2.2, H-
NHBocNH2
N
NH2
Cl
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C(6)), 6.62 (d, J = 5.3, H-C(3)). 13C NMR (125 MHz, CD3OD, δ): 155.55, 152.11, 150.18, 
136.66, 127.55, 125.93, 125.14, 118.48, 104.03. HRMS: m/z 179.03700 corresponds to 
molecular formula C9H7ClN2H+ (error in ppm -0.32). 
 
N'-(7-Chloro-3-nitroquinolin-4-yl)-N,N-diethylpropane-1,3-diamine (1). 
Compound 1 was synthesized from 31 (50.0 mg, 0.206 mmol) and 
3-diethylamino-1-propilamine (0.05 mL, 0.32 mmol) by procedure 
A. The product was purified using column chromatography (dry-
flash, SiO2, eluent MeOH, EtOAc/(MeOH/NH3=9/1) gradient 9/1 → 1/1 and flash 
chromatography, Biotage SP1, NH column, eluent EtOAc/Hex gradient 8/2). Final product 1 was 
obtained as a bright yellow solid (53.8 mg, 78%); softens at 50 ºC. IR (ATR): 3122m, 2968s, 
2876m, 2839m, 1566s, 1517s, 1448m, 1396m, 1342m, 1284m, 1254s, 1215m, 1191m, 1157m, 
1116m, 1088w, 1021w, 980w, 958w, 924w, 892w, 819m, 774w, 719w, 596w cm-1. 1H NMR 
(500 MHz, CDCl3, δ): 9.97 (s, H-N), 9.26 (s, H-C(2)), 8.19 (d, J = 8.9, H-C(5)), 7.95 (d, J = 2.3, 
H-C(8)), 7.40 (dd, J1 = 9.0, J2 = 2.2, H-C(6)), 3.85 (q, 2H, J = 6.0, ArNHCH2-), 2.66 (t, 2H, J = 
6.2, -CH2N(CH2CH3)2), 2.59 (q, 4H, J = 7.1, -N(CH2CH3)2), 1.94-1.89 (m, 2H, ArNHCH2CH2-), 
1.04 (t, 6H, J = 7.1, -N(CH2CH3)2). 13C NMR (125 MHz, CDCl3, δ): 150.88, 149.73, 148.64, 
138.32, 129.31, 127.38, 126.12, 125.82, 118.07, 50.72, 48.57, 46.98, 27.60, 11.31. HRMS: m/z 
337.14259 corresponds to molecular formula C16H21ClN4O2H+ (error in ppm 0.03); m/z 
169.07533 corresponds to molecular formula C16H21ClN4O2H22+ (error in ppm 2.39). HPLC 
purity (λ = 330 nm) method A: RT 9.953 min, area 98.91%; method B: RT 8.598 min, area 
95.44%. 
 
N4-(7-Chloro-3-nitroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine (2). 
Compound 2 was synthesized from 31 (75 mg, 0.31 mmol) and 2-
amino-5-diethylaminopentane (0.09 mL, 0.46 mmol) by procedure 
A. The product was purified using column chromatography (dry-
flash, SiO2, eluent EtOAc/(MeOH/NH3=9/1) gradient 8/2 → 1/1 and 
flash chromatography, Biotage SP1, NH column, eluent EtOAc/MeOH gradient EtOAc → 97/3). 
Final product 2 was obtained as a bright yellow oil (88.0 mg, 78%). IR (ATR): 3272w, 2968m, 
2930m, 2870w, 2804w, 1606m, 1578s, 1530m, 1450m, 1410m, 1382m, 1276m, 1249m, 1228m, 
NCl
NO2
NH
N
NCl
NO2
NH N
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1189w, 1155m, 1110w, 950w, 883w, 822w, 778w cm-1. 1H NMR (500 MHz, CDCl3, δ): 9.46 (d, 
J = 8.7, H-N), 9.35 (s, H-C(2)), 8.13 (d, J = 9.2, H-C(5)), 7.97 (d, J = 2.0, H-C(8)), 7.43 (dd, J1 = 
9.2, J2 = 2.3, H-C(6)), 4.4.-4.32 (m, 1H, ArNHCH(CH3)-), 2.46 (q, 4H, J = 7.1, -N(CH2CH3)2), 
2.38 (t, 2H, J = 7.3, -CH2N(CH2CH3)2), 1.82-1.69 (m, 2H, ArNHCH(CH3)CH2-), 1.58-1.46 (m, 
5H, -CH2CH2N(CH2CH3)2, ArNHCH(CH3)-), 0.96 (t, 6H, J = 7.2, -N(CH2CH3)2). 13C NMR (125 
MHz, CDCl3, δ): 151.27, 150.38, 148.56, 138.71, 129.56, 127.75, 126.52, 126.19, 117.79, 54.63, 
52.24, 46.74, 36.77, 23.73, 22.12, 11.51. HRMS: m/z 365.17392 corresponds to molecular 
formula C18H25ClN4O2H+ (error in ppm 0.10); m/z 183.09120 corresponds to molecular formula 
C18H25ClN4O2H22+ (error in ppm 3.42). HPLC purity (λ = 330 nm) method A: RT 10.947 min, 
area 98.75%; method B: RT 8.985 min, area 97.28%. 
 
 
7-Chloro-N4-[3-(diethylamino)propyl]quinoline-3,4-diamine (3). 
Compound 3 was prepared by procedure B using 1 (10.3 mg, 0.0306 
mmol) and SnCl2 (29.0 mg, 0.153 mmol). The product was purified 
using column chromatography (dry-flash, SiO2, eluent 
DCM/(MeOH/NH3=9/1) = 9/1). Final product 3 was obtained as a brown oil (3.8 mg, 40%). IR 
(ATR): 3313s, 2969s, 2930s, 2817m, 1596s, 1564s, 1468m, 1380s, 1344s, 1198m, 1166w, 
1133m, 1075m, 988w, 897w, 815m, 767w, 673w, 548w, 436w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 8.41 (s, H-C(2)), 7.92 (d, J = 2.1, H-C(8)), 7.85 (d, J = 9.2, H-C(5)), 7.35 (dd, J1 = 
9.2, J2 = 2.1, H-C(6)), 4.77 (bs, H-N), 4.08 (bs, -NH2), 3.38 (t, 2H, J = 6.0, ArNHCH2), 2.73-
2.68 (m, 6H, -CH2N(CH2CH3)2, -N(CH2CH3)2), 1.90-1.85 (m, 2H, ArNHCH2CH2-), 1.12 (t, 6H, 
J = 7.2, -N(CH2CH3)2). 13C NMR (125 MHz, CDCl3, δ): 144.58, 144.24, 135.92, 131.03, 130.74, 
128.58, 126.21, 122.17, 121.93, 51.14, 46.38, 45.27, 26.88, 10.66. HRMS: m/z 307.16817 
corresponds to molecular formula C16H23ClN4H+ (error in ppm -0.76); m/z 154.08791 
corresponds to molecular formula C16H23ClN4H22+ (error in ppm 0.48). HPLC purity (λ = 270 
nm) method A: RT 9.241 min, area 97.15%; method B: RT 7.692 min, area 95.76%. 
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7-Chloro-N4-[4-(diethylamino)-1-methylbutyl]quinoline-3,4-diamine (4). 
Compound 4 was prepared by procedure B using 2 (64.7 mg, 0.177 
mmol) and SnCl2 (168.1 mg, 0.8865 mmol). The product was 
purified using column chromatography (dry-flash, SiO2, eluent 
DCM/(MeOH/NH3=9/1) = 9/1). Final product 4 was obtained as a 
brown oil (35.8 mg, 60%). IR (ATR): 3323s, 2968s, 2816m, 1597s, 1564s, 1488m, 1378s, 1347s, 
1196w, 1131m, 984w, 900w, 876w, 820m, 767m, 548w, 429w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 8.45 (s, H-C(2)), 7.94 (d, J = 2.3, H-C(8)), 7.73 (d, J = 8.9, H-C(5)), 7.37 (dd, J1 = 
8.9, J2 = 2.3, H-C(6)), 3.78 (bs, -NH2 exchangeable with D2O), 3.56 (bs, H-N exchangeable with 
D2O), 2.57-2.37 (m, 7H, ArNHCH(CH3)-, -CH2N(CH2CH3)2, -N(CH2CH3)2), 1.68-1.49 (m, 4H, 
ArNHCH(CH3)CH2-, ArNHCH(CH3)CH2CH2-), 1.14 (d, 3H, J = 6.2, ArNHCH(CH3)-), 1.00 (t, 
6H, J = 7.1, -N(CH2CH3)2). 13C NMR (125 MHz, CDCl3, δ): 144.64, 144.42, 134.89, 131.52, 
131.18, 128.75, 126.56, 122.89, 121.77, 52.90, 51.18, 46.87, 36.42, 23.97, 21.94, 11.47. HRMS: 
m/z 335.19970 corresponds to molecular formula C18H27ClN4H+ (error in ppm 0.00); m/z 
168.10399 corresponds to molecular formula C18H27ClN4H22+ (error in ppm 2.97). HPLC purity 
method A (λ = 254 nm): RT 8.866 min, area 95.57%; method B (λ = 270 nm): RT 7.883 min, 
area 95.56%. 
 
N-(1-adamantylmethyl)-N'-(7-chloro-3-nitroquinolin-4-yl)propane-1,3-diamine (5).  
A solution of 33 (62.0 mg, 0.279 mmol) in DCM (3 mL) was 
cooled to 0 ºC. Then, 31 (45.2 mg, 0.186 mmol) was added 
and stirring continued at same temperature for 15 min. 
Mixture was allowed to warm to r.t. and after another 15 
minutes heated to reflux for 2h. Water was added and product 
extracted several times with DCM. Combined organic layers were dried over anh. NaSO4 and the 
solvent was evaporated under reduced pressure. The product was purified using column 
chromatography (dry-flash, SiO2, eluent EtOAc → EtOAc/MeOH = 1/1 and flash 
chromatography, Biotage SP1, NH column, eluent EtOAc/Hex gradient 6/4 → 8/2). Final 
product 5 was obtained as a bright yellow oil (57.5 mg, 72%). IR (ATR): 3334w, 3246w, 2901s, 
2844s, 1582s, 1530m, 1449m, 1416m, 1342m, 1279m, 1248m, 1218m, 1187m, 1155m, 1118m, 
952w, 899w, 826w, 775w, 704w, 626w cm-1. 1H NMR (500 MHz, CDCl3, δ): 9.74 (bs, H-N 
NCl
NH2
NH
N
N
HN
H
N
Cl
NO2
S14 
 
exchangeable with D2O), 9.32 (s, H-C(2)), 8.26 (d, J = 9.2, H-C(5)), 7.96 (d, J = 2.1, H-C(8)), 
7.41 (dd, J1 = 9.0, J2 = 2.2, H-C(6)), 3.98-3.95 (m, 2H, ArNHCH2-), 2.80 (t, 2H, J = 6.3, -
CH2NHCH2Ad), 2.24 (s, 2H, -CH2Ad), 1.97-1.92 (m, 5H, ArNHCH2CH2-, -Ad), 1.72-1.70 (m, 
3H, -Ad), 1.63-1.60 (m, 3H, -Ad), 1.48 (d, 6H, J = 2.1, -Ad). 13C NMR (125 MHz, CDCl3, δ): 
151.20, 150.38, 148.63, 138.59, 129.39, 127.96, 126.14, 125.90, 118.00, 62.96, 48.14, 47.89, 
40.86, 37.16, 33.47, 30.73, 28.41. HRMS: m/z 429.20526 corresponds to molecular formula 
C23H29ClN4O2H+ (error in ppm 0.20); m/z 215.10664 corresponds to molecular formula 
C23H29ClN4O2H22+ (error in ppm 1.92). HPLC purity method A (λ = 270 nm): RT 11.811 min, 
area 95.51%; method B (λ = 330 nm): RT 10.885 min, area 97.86%. 
 
N4-{3-[(1-adamantylmethyl)amino]propyl}-7-chloroquinoline-3,4-diamine (6). 
Compound 6 was synthesized by procedure B using 5 (36.7 
mg, 0.086 mmol) and SnCl2 (81.2 mg, 0.428 mmol). The 
product was purified using column chromatography (dry-
flash, SiO2, eluent DCM/(MeOH/NH3=9/1) = 9/1). Final 
product 6 was obtained as a yellowish foam (24.2 mg, 71%); 
softens at 30-32 ºC. IR (ATR): 3312m, 2901s, 2845s, 1597m, 1564m, 1453m, 1344m, 1198w, 
1119w, 897w, 814w, 734w, 548w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.43 (s, H-C(2)), 7.93 
(d, J = 2.1, H-C(8)), 7.84 (d, J = 9.2, H-C(5)), 7.34 (dd, J1 = 9.2, J2 = 2.1, H-C(6)), 4.03 (bs, H-N 
exchangeable with D2O), 3.33 (t, 2H, J = 6.1, ArNHCH2-), 2.86 (t, 2H, J = 6.0, -CH2NHCH2Ad), 
2.32, (s, 2H, -CH2Ad), 1.98 (bs, 3H, -Ad), 1.86-1.81 (m, 2H, ArNHCH2CH2-), 1.74-1.72 (m, 3H, 
-Ad), 1.66-1.63 (m, 3H, -Ad), 1.56 (d, 6H, J = 2.4, -Ad). 13C NMR (125 MHz, CDCl3, δ): 
144.54, 144.30, 135.88, 131.32, 131.01, 128.63, 126.37, 122.34, 122.11, 63.53, 49.65, 46.01, 
41.09, 37.15, 33.32, 29.84, 28.40. HRMS: m/z 399.22992 corresponds to molecular formula 
C23H31ClN4H+ (error in ppm - 2.71); m/z 200.11926 corresponds to molecular formula 
C23H31ClN4H22+ (error in ppm 0.62). HPLC purity method A (λ = 254 nm): RT 10.495 min, area 
96.03%; method B (λ = 270 nm): RT 9.666 min, area 98.63%. 
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4-({3-[4-(3-{[2-(1-adamantyl)ethyl]ammonio}propyl)piperazinediium-1-yl]propyl}amino)-
7-chloroquinolinium tetrachloride (10). 
Amine 38 (50 mg, 0.098 mmol) was suspended in 0.5 mL 
EtOH, followed by addition of EtOH/HCl solution (2 mL, 
25%) and the reaction mixture was vigorously stirred 24h at 
r.t. Formed solid was filtered and washed well with 96% 
EtOH (5 mL) and Et2O (5 mL). Upon drying at r.t. under 
reduced pressure desired salt was obtained (55 mg, 85%). 
M.p. > 280 oC. IR (ATR): 3383s, 3107w, 2902s, 2846m, 
2657w, 2516w, 2437w, 2367w, 2325w, 2191w, 2121w, 
2029w, 2006w, 1988w, 1965w, 1922w, 1615s, 1451s, 
1362m, 1246w, 1216m, 1170w, 1141w, 1097w, 1052w, 1022w, 954m, 905m, 815m, 766m, 
656w, 602w cm-1. 1H NMR (500 MHz, D2O): 8.36 (d, 1H, J = 7.0 Hz, H-C(2)), 8.20 (d, 1H, J = 
9.3 Hz, H-C(5)), 7.90 (d, 1H, J = 1.6 Hz, H-C(8)), 7.69 (dd, 1H, J = 1.9 Hz, J = 9.0 Hz, H-C(6)), 
6.87 (d, 1H, J = 7.0 Hz, H-C(3)), 3.80-3.70 (m, 2H, ArNHCH2-), 3,70-3,55 (m, 8H, -
NH+(CH2CH2)2NH+-), 3,50-3,40 (m, 2H, ArNHCH2CH2CH2NH+(CH2CH2)2NH+-), 3,35-3,25 
(m, 2H, -NH(CH2CH2)2NH+CH2CH2CH2NH2+CH2CH2Ad), 3,20-3,05 (m, 4H, -
CH2NH2+CH2CH2Ad, -CH2CH2Ad), 2.35-2.25 (m, 2H, ArNHCH2CH2-), 2.20-2.10 (m, 2H, -
CH2CH2NH2+CH2CH2Ad),   2.00-1.90 (m, 3H, -Ad), 1.80-1.60 (m, 6H, -Ad), 1.60-1.50 (m, 6H, -
Ad), 1.50-1.40 (m, 2H, -CH2Ad). 13C NMR (125 MHz, D2O): 156.11; 142.34; 139.40; 138.06; 
127.56; 124.02; 119.16; 115.34; 98.32; 54.28; 53.53; 49.25; 49.06; 44.20; 43.56; 41.34; 40.02; 
39.37; 36.26; 31.06; 28,14, 22.50, 21.01. HRMS: m/z 524.35077 corresponds to molecular 
formula C31H46ClN5H+ (error in ppm -1.30). HPLC purity (λ=330 nm): method A: RT 9.973, 
area 98.31%; method B: RT 8.296, area 95.32%. Anal. (C31H46ClN5 × 4HCl × 3.5H2O) Calcd: C, 
50.79; H, 7.84; N, 9.55. Found: C, 50.89; H, 7.80; N, 9.62. 
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N-(7-chloroquinolin-4-yl)-N'-[4-(5-fluoro-1-benzothiophene-3-yl)benzyl]propane-1,3-
diamine (15). 
Compound 15 was prepared by procedure D, 
using aldehyde 3911 (118 mg, 0.460 mmol), 
amine AQ3 (162.8 mg, 0.6906 mmol), glac. 
AcOH (40 μL, 0.7 mmol), NaBH4 (104.5 mg, 
2.762 mmol) and MeOH/ DCM (18 mL, 2:1, 
v/v). The product was purified using column chromatography (flash, Biotage SP1, NH column, 
eluent hexane/EtOAc gradient 2/8 → EtOAc, EtOAc/MeOH gradient 95/5 → 1/1, MeOH; flash, 
Biotage SP1, SiO2 column, eluent DCM /MeOH+NH3 (9/1) gradient 95/5 → 3/7). Final product 
15 was obtained as a pale yellow foam (156.5 mg, 71%). M.p. = 39 – 40 ºC. IR (ATR): 3239w, 
3062w, 2935w, 2844w, 1583s, 1537m, 1492w, 1437m, 1368w, 1332w, 1282w, 1251w, 1197w, 
1138w, 1114w, 883w, 853w, 806m, 784w, 650w cm-1. 1H NMR (500MHz, CDCl3): 8.50 (d, J = 
5.3, H-C(2')), 7.92-7.90 (m, H-C(8')), 7.84 (dd, J1 = 4.8, J2 = 8.9, H-C(7)), 7.59-7.53 (m, 5H, 2H-
Ar, H-C(4), H-C(5') and H-N exchangeable with D2O), 7.50 (s, H-C(2)), 7.48-7.44 (m, 2H-Ar), 
7.19-7.11 (m, 2H, H-C(6) and H-C(6')), 6.32 (d, J = 5.2, H-C(3')), 3.92 (s, 2H, ArCH2NH-), 
3.45-3.40 (m, 2H, ArNHCH2-), 3.05-3.01 (m, 2H, ArCH2NHCH2-), 2.02-1.95 (m, 2H 
ArCH2NHCH2CH2-), 1.86 (bs, H-N exchangeable with D2O). 13C NMR (125 MHz, CDCl3): 
161.13 (d, J = 240.7), 152.13, 150.40, 149.15, 139.14, 138.98, 137.37 (d, J = 4.7), 136.03, 
134.70, 134.58, 128.83, 128.74, 128.53, 125.86, 124.79, 124.05 (d, J = 8.5), 122.04, 117.50, 
113.40 (d, J = 25.6), 108.45 (d, J = 23.7), 98.32, 54.01, 49.32, 43.97, 27.45. HRMS: m/z 
476.13504 corresponds to molecular formula C27H23ClN3SFH+ (error in ppm -1.60), m/z 
238.57136 corresponds to molecular formula C27H23ClN3SFH22+ (error in ppm -0.75). HPLC 
purity: method C (λ = 330 nm): RT 9.741, area 96.57%; method D (λ = 254 nm): RT 5.816, area 
95.63%. 
 
N-[3-(5-fluoro-1-benzothien-3-yl)prop-2-yn-1-yl]-N'-quinolin-4-ylbutane-1,4-diamine (21). 
Solution of 40 (11.7 mg, 0.0507 mmol) in DMF (0.1 
mL), PdCl2(PPh3)2 (2.1 mg, 6.0 mol%), PPh3 (2.6 
mg, 20 mol%), solution of 41 (10.7 mg, 0.0422 
mmol) in DMF (0.1 mL), CuI (0.6 mg, 6 mol%) and 
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Et2NH (78 μL, 0.71 mmol) were added to a dry microwave tube (0.2-0.5 mL) under Ar 
atmosphere. The mixture was heated in microwave reactor (Biotage Initiator 2.5 apparatus) at 
120 °C for 25 minutes. After cooling to r.t. the reaction mixture was transferred to the separation 
funnel and DCM was added. Organic layer was washed with brine (with addition of 1 drop of 
aqueous NH3) and dried over anh. Na2SO4. Crude product was purified using column 
chromatography (flash, Biotage SP, NH column, 12+M, eluent hexane/EtOAc gradient 2/8 → 
EtOAc, EtOAc/MeOH gradient 9/1 → 1/1). Final product 21 was obtained as yellow oil (5.4 mg, 
27%). IR (ATR): 3440w, 3250m, 3067m, 2930m, 2858m, 1582s, 1542m, 1442m, 1396w, 
1374w, 1340m, 1298w, 1248w, 1196w, 1129w, 1100w, 1036w, 947w, 874w, 808w, 764m, 
736w, 650w cm-1. 1H NMR (200 MHz, CDCl3, δ): 8.53 (d, J = 5.6, H-C(2')), 8.01-7.93 (m, H-
C(8')), 7.83-7.71 (m, 2H, H-C(5') and H-C(7)), 7.70-7.50 (m, 3H, H-C(7'), H-C(4) and H-C(2)), 
7.45-7.34 (m, H-C(6')), 7.21-7.08 (m, H-C(6)), 6.40 (d, J = 5.6, H-C(3')), 5.72 (bs, H-N), 3.78 (s, 
2H, -CH2C≡C-Ar), 3.41-3.29 (m, 2H, ArNHCH2-), 2.98-2.87 (m, 2H, ArNH(CH2)3CH2-), 2.01-
1.68 (m, 5H, ArNHCH2CH2CH2- and H-N). 13C NMR (125 MHz, CDCl3, δ): 161.21 (d, J = 
241.9), 150.66, 150.04, 147.99, 134.12, 131.93, 129.50, 129.05, 124.53, 123.82 (d, J = 9.0), 
119.62, 118.74, 117.95, 113.99 (d, J = 25.3), 111.78, 108.52 (d, J = 23.5), 98.55, 90.30, 76.47, 
48.12, 43.18, 39.11, 27.57, 26.43. HRMS: m/z 404.15750 corresponds to molecular formula 
C24H22FN3SH+ (error in ppm -4.00). HPLC purity (λ = 254 nm): method A: RT 10.106, area 
96.11%; method B: RT 8.432, area 95.69%. 
 
N1,N1-diethyl-N3-(5,6,7,8-tetrahydroquinolin-4-yl)propane-1,3-diamine (22). 
Compound 22 was prepared by procedure E, using Pd(OAc)2 (1.4 mg, 
0.0064 mmol), SPhos (5.2 mg, 0.013 mmol), 45 (26.8 mg, 0.159 mmol), 
N,N-diethylpropane-1,3-diamine (38 µL, 0.24 mmol), K3PO4 (84.6 mg, 
0.398 mmol) and dioxane (1.3 mL). Final product 22 was obtained as colorless oil (18 mg, 43 
%). IR (ATR): 3266w, 2968m, 2933m, 2873m, 2831m, 1591s, 1518m, 1452m, 1375w, 1343w, 
1166w, 1139w, 1067w, 801 cm-1. 1H NMR (200 MHz, CDCl3, δ): 8.06 (d, J = 5.6, H-C(2)), 6.26 
(d, J = 5.6, H-C(3)), 5.94 (bs, H-N), 3.35-3.10 (m, 2H, -CH2HN-), 2.90-2.70 (m, 2H), 2.65-2.45 
(m, 6H), 2.40-2.25 (m, 2H), 1.95-1.65 (m, 6H), 1.03 (t, 3H, J = 7.0, -CH2CH3). 13C NMR (50 
MHz, CDCl3, δ): 155.41, 147.13, 115.32, 101.84, 52.74, 46.73, 43.64, 32.68, 25.27, 23.17, 
22.72, 22.54, 11.38. HRMS: m/z 262.22666 corresponds to molecular formula C16H27N3H+ (error 
N
NH N
S18 
 
in ppm -4.25). HPLC purity (λ = 290 nm): method A: RT 1.353, area 96.66%; method E: RT 
4.016, area 99.41%. 
 
N1,N1-diethyl-N4-(5,6,7,8-tetrahydroquinolin-4-yl)pentane-1,4-diamine (23). 
Compound 23 was prepared by procedure E, using Pd(OAc)2 (1.1 mg, 
0.0049 mmol), SPhos (4.1 mg, 0.0010 mmol), 45 (21 mg, 0.12 mmol), 
N1,N1-diethylpentane-1,4-diamine (29.7 mg, 0.188 mmol), K3PO4 (66.5 
mg, 0.312 mmol) and dioxane (1 mL). Final product 23 was obtained as 
colorless oil (9.9 mg, 27 %). IR (ATR): 3314w, 2967s, 2932s, 2865m, 
2802m, 1589s, 1513m, 1452m,1371w, 1342w, 1165w, 805 cm-1. 1H NMR (200 MHz, CDCl3, δ): 
8.07 (d, J = 5.6, H-C(2)), 6.32 (d, J = 5.6, H-C(3)), 3.85-3.70 (m, H-N), 3.65-3.47 (m, -CH-CH3), 
2.95-2.71 (m, 2H), 2.60-2.25 (m, 8H), 1.95-1.75 (m, 4H), 1.63-1.44 (m, 4H), 1.22 (d, 3H, J = 
6.7, -CH-CH3), 1.00 (t, 6H, J = 7.0, -CH2CH3). 13C NMR (125 MHz, CDCl3, δ): 155.88, 150.68, 
146.96, 114.97, 102.50, 52.75, 47.75, 46.79, 34.85, 32.75, 23.76, 22.79, 22.61, 22.52, 20.74, 
11.56. HRMS: m/z 290.25771 corresponds to molecular formula C18H31N3H+ (error in ppm -
4.69). HPLC purity (λ = 290 nm): method A: RT 8.644, area 97.25%; method E: RT 4.084, area 
97.18%. 
 
4-{5-[4-({[8-(5,6,7,8-tetrahydroquinolin-4-ylamino)octyl]amino}methyl)phenyl]-2-
thienyl}benzonitrile (24). 
Compound 24 was prepared 
by procedure D, using 
aldehyde 4-[5-(4-
formylphenyl)thiophen-2-
yl]benzonitrile11 (61 mg, 0.21 mmol), amine 46 (87 mg, 0.32 mmol), glac. AcOH (19 μL, 0.32 
mmol), NaBH4 (47.9 mg, 1.27 mmol) and MeOH/ DCM (9 mL, 2:1, v/v). The product was 
purified using column chromatography (dry flash, silica-gel, eluent EtOAc/MeOH and flash, 
Biotage SP, NH column, eluent EtOAc/MeOH). Final product 24 was obtained as pale yellow 
solid (37 mg, 32%). M.p. = 155 – 157 ºC. IR (film): 3328m, 2930s, 2856s, 2869m, 2221m, 
1701w, 1670w, 1653m, 1590s, 1524s, 1494m, 1452m, 1347m, 1310m, 1277m, 1166m, 1098w, 
804m cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.07 (d, J = 5.7, H-C(2)), 7.74-7.53 (m, 6H, 4H-
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ArCN and 2H-Ar), 7.45-7.28 (m, 4H, 2H-Ar and 2H-Thiophene), 6.30 (d, J = 5.7, H-C(3)), 3.80 
(s, 2H, ArCH2-), 3.24-3.08 (m, 2H, ArNHCH2-), 2.88-2.74 (m, 2H), 2.70-2.55 (m, 2H, 
ArCH2NHCH2-), 2.41-2.27 (m, 2H), 1.89-1.75 (m, 4H), 1.68-1.58 (m, 2H), 1.56-1.46 (m, 2H), 
1.43-1.28(m, 8H, -(CH2)4-). 13C NMR (125 MHz, CDCl3, δ): 155.56, 151.54, 146.92, 145.99, 
140.80, 138.53, 132.72, 132.34, 128.74, 126.06, 125.77, 125.64, 124.16, 118.84, 115.00, 110.37, 
102.21, 53.68, 49.45, 42.96, 32.56, 30.08, 29.43, 29.27, 29.21, 27.24, 26.98, 22.69, 22.60, 22.48.  
HRMS: m/z 549.30216 corresponds to molecular formula C35H40N4SH+ (error in ppm -4.52). 
HPLC purity (λ = 330 nm): method A: RT 8.837, area 97.08%; method B: RT 7.689, area 
95.53%. 
 
4-{5-[4-({methyl[8-(5,6,7,8-tetrahydroquinolin-4-ylamino)octyl]amino}methyl)phenyl]-2-
thienyl}benzonitrile (25). 
To a stirred solution of 24 
(19 mg, 0.035 mmol) in 
methanol (0.9 mL) 
containing 37% aqueous 
formaldehyde (2.1 mg, 0.069 mmol), mixture of ZnCl2 (9.4 mg, 0.069 mmol) and NaBH3CN (8.7 
mg, 0.14 mmol) in methanol (0.9 mL) was added. The mixture was stirred at r. t. for 2h. The 
solvent was removed under reduced pressure. The residue was dissolved in DCM and 2M NH3, 
organic layer was washed with brine and dried over anhydrous Na2SO4. The product was 
purified using column chromatography (flash, Biotage SP1, NH column, eluent MeOH). Final 
product 25 was obtained as pale yellow oil (16.4 mg, 84%). IR (film): 3267m, 3054m, 2928s, 
2855s, 2225m, 1634s, 1600s, 1567s, 1537m, 1454m, 1374m, 1274m, 1175m, 1114w, 837m, 
806m, 735m cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.08 (d, J = 5.7, H-C(2)), 7.72-7.62 (m, 4H, 
H-ArCN), 7.60-7.55 (m, 2H, H-Ar), 7.41-7.27 (m, 4H, 2H-thiophene and 2H-Ar), 6.30 (d, J = 
6.3, H-C(3)), 3.49 (s, 2H, ArCH2NH-), 3.20-3.10 (m, 2H), 2.89-2.75 (m, 2H), 2.43-2.27 (m, 4H), 
2.20 (s, 3H, CH3-), 1.90-1.78 (m, 4H), 1.68-1.58 (m, 4H), 1.57-1.47 (m, 2H), 1.43-1.28 (m, 8H, -
(CH2)4-). 13C NMR (125 MHz, CDCl3, δ): 155.81, 151.40, 147.21, 146.07, 140.64, 139.70, 
138.55, 132.72, 132.30, 129.61, 126.06, 125.63, 125.57, 124.12, 118.85, 114.97, 110.34, 102.22, 
61.99, 57.48, 42.97, 42.31, 32.79, 29.42, 29.30, 29.23, 27.38, 27.29, 27.02, 22.72, 22.67, 22.54. 
HRMS: m/z 563.31839 corresponds to molecular formula C36H42N4SH+ (error in ppm -3.38). 
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HPLC purity (λ = 330 nm): method A: RT 8.651, area 96.45%; method B: RT 7.691, area 
95.11%. 
 
tert-Butyl {3-[(1-adamantylmethyl)amino]propyl}carbamate (32). 
1-Adamantylmethanol (185.8 mg, 1.118 mmol) was dissolved in 
DCM (15 mL) followed by addition of PCC (361.3 mg, 1.676 
mmol). The mixture was stirred at r.t. for 2h and filtered through 
SiO2 column (eluent DCM) to afford the product. Adamantane-1-carbaldehyde was obtained as a 
white foam and used in the next step without characterization. Compound 32 was prepared by 
procedure D from S1 (218.7 mg, 1.255 mmol) and adamantane-1-carbaldehyde (167.2 mg, 1.018 
mmol) using glac. AcOH (0.09 mL, 1.6 mmol) and NaBH4 (231.1 mg, 6.109 mmol). The product 
was purified using column chromatography (dry-flash, SiO2, eluent DCM/MeOH gradient 4/6 → 
2/8). Final product 32 was obtained as a pale yellow oil (134.8 mg, 37% for both steps). IR 
(ATR): 3345s, 3054w, 3007w, 2977m, 2904s, 2847m, 2782w, 2738w, 2658w, 1674s, 1538s, 
1479m, 1450m, 1427w, 1390w, 1364m, 1341w, 1315w, 1281s, 1253m, 1227w, 1169m, 1114w, 
1028w, 1000w, 948w, 897w, 866w, 800w, 781w, 754w, 719w, 654w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 6.06 (bs, H-NBoc), 3.22 (q, 2H, J = 5.2, -CH2NHBoc), 2.69 (t, 2H, J = 6.0, -
CH2NHCH2Ad), 2.23 (s, 2H, -NHCH2Ad), 1.97 (bs, 3H, -Ad), 1.73-1.62 (m, 8H, -
CH2CH2NHBoc, -Ad), 1.53 (d, 6H, J = 2.4, -Ad), 1.43 (s, 9H, -NHCOOC(CH3)3). 13C NMR 
(125 MHz, CDCl3, δ): 156.20, 78.56, 62.78, 49.70, 40.89, 40.45, 37.21, 33.31, 28.72, 28.46, 
28.44. HRMS: m/z 323.26898 corresponds to molecular formula C19H34N2O2H+ (error in ppm - 
1.01). 
 
N-(1-adamantylmethyl)propane-1,3-diamine (33). 
Compound 33 was prepared from 32 (10.0 mg, 0.031 mmol) by 
procedure C. Final product 33 was obtained as a pale yellow oil (6.0 
mg, 87%). IR (ATR): 3290w, 2900s, 2845s, 2676w, 1571w, 1475m, 
1408w, 1364w, 1341w, 1315w, 1222w, 1152w, 1100w, 1002w, 814w cm-1. 1H NMR (500 MHz, 
CDCl3, δ): 2.76 (t, 2H, J = 6.9, -CH2NH2), 2.64 (t, 2H, J = 7.0, -CH2NHCH2Ad), 2.24 (s, 2H, -
NHCH2Ad), 1.96 (bs, 3H, -Ad), 1.73-1.60 (m, 8H, -CH2CH2NH2, -Ad), 1.52 (d, 6H, J = 2.4, -
Ad). 13C NMR (125 MHz, CDCl3, δ): 63.12, 49.03, 40.95, 40.74, 37.24, 33.72, 33.34, 28.48. 
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HRMS: m/z 223.21604 corresponds to molecular formula C14H26N2H+ (error in ppm - 3.73); m/z 
112.11222 corresponds to molecular formula C14H26N2H22+ (error in ppm 1.28). 
 
Di-tert-butyl [piperazine-1,4-diylbis(propane-3,1-diyl)]biscarbamate (35). 
A 0.5 M solution of Boc2O (2.12 g, 9.71 mmol) in DCM was added 
dropwise over 2 h to a 0.25 M solution of 1,4-bis(3-
aminopropyl)piperazine 34 (4 mL, 19 mmol) in DCM cooled with an 
ice-bath. The reaction mixture was stirred overnight at r.t., filtered and 
then concentrated in vacuo. The resulting oil was dissolved in EtOAc, 
washed with with half-saturated brine, dried over MgSO4 and solvent 
was evaporated under reduced pressure. Compound 35 was obtained 
after dry-flash chromatography: (SiO2, eluent: DCM/MeOH(NH3 satd) = 95/5) as a colorless 
solid (1.79 g, 46%); M.p. = 73-75 C (hexane). IR (ATR): 3200m, 3008w, 2960m, 2869w, 
2811m, 2744w, 2020w, 1712s, 1553m, 1457w, 1387w, 1362w, 1272m, 1169m, 1114w, 1084w, 
1032w, 1005w, 972m, 888w, 856w, 819w, 764w, 733w, 693w cm-1. 1H NMR (500 MHz, 
CDCl3): 3.30-3.05 (m, 2H, -CH2NHBoc), 2.75-2.25 (m, 12H, -CH2N(CH2CH2)2NCH2-, -
N(CH2CH2)2N-), 1.85-1.55 (m, 2H, -CH2CH2NHBoc), 1.44 (s, 18H, -NHCOO-C(CH3)3). 13C 
NMR (125 MHz, CDCl3): 156.04; 78.74; 56.84; 53.20; 39.97; 28.42; 26.30. HRMS: m/z 
401.31137 corresponds to molecular formula C15H32N4O2H+ (error in ppm -2.15).  
 
Tert-butyl [3-(4-{3-[(7-chloroquinolin-4-yl)amino]propyl}piperazin-1-yl)propyl]carbamate 
(36).  
A mixture of 4,7-dichloroquinoline (1.75 g, 17.7 mmol) and 
protected diaminoalkane 35 (5.32 g, 17.7 mmol)  was gradually 
warmed to 80 °C over 1h with stirring and subsequently at 125 °C 
for 6-8 h. The reaction mixture was cooled to r.t. and taken up in 
DCM. The organic layer was washed with NaHCO3 and finally 
with brine. The organic layer was dried over anhydrous Na2SO4 and 
solvent was evaporated under reduced pressure to get a final 
product. Compound 36 was obtained after dry-flash 
chromatography (SiO2, eluent: DCM/MeOH(NH3 satd) = 100/2) as 
NCl
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a colorless solid (4.0 g, 63%); M.p. = 148-150 C (hexane). IR (ATR): 3215m, 3032w, 2943w, 
2876w, 2807w, 2771w, 1709s, 1611w, 1582s, 1537m, 1487w, 1466w, 1447w, 1361w, 1333w, 
1308w, 1274m, 1252w, 1170m, 1149m, 1137m, 1102w, 1078w, 1063w, 1032w, 987w, 974w, 
947w, 890w, 880w, 856w, 838w, 812w, 764w, 710w, 652w, 599w, 503w, 425w cm-1. 1H NMR 
(200 MHz, CDCl3/CD3OD): 8.40 (d, 1H, J = 5.6 Hz, H-C(2)), 7.95-7.80 (m, 2H, H-C(8) and H-
C(5)), 7.40-7.25 (m, 1H, H-C(6)), 6.34 (d, 1H, J = 5.6 Hz, H-C(3)), 3.50-3.30 (m, 2H, 
ArNHCH2-), 3.30-3.10 (m, 2H, -CH2NHBoc), 3.00-2.30 (m, 12H, -CH2N(CH2CH2)2NCH2-, -
N(CH2CH2)2N-), 2.10-1.80 (m, 2H, ArNHCH2CH2-), 1.80-1.60 (m, 2H, -CH2CH2NHBoc), 1.46 
(s, 9H, -NHCOO-C(CH3)3). 13C NMR (50 MHz, CDCl3/CH3OD): 156.26; 151.34; 150.68; 
148.26; 134.84; 127.38; 124.68; 122.26; 117.11; 98.21; 78.93; 57.81; 57.56; 56.37; 53.22; 53.02; 
52.89; 43.04; 39.07; 28.15; 26.22; 23.54. HRMS: m/z 462.26263 corresponds to molecular 
formula C24H36ClN5O2H+ (error in ppm -0.87). (C24H36ClN5O2×1/3H2O) Calcd: C, 61.59; H, 
7.90; N, 14.96. Found: C, 61.46; H, 7.75; N, 15.23. 
 
N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-7-chloroquinolin-4-amine (37). 
Compound 37 was prepared from 36 (500 mg, 1 mmol) by procedure 
C and was obtained as a yellow powder (348 mg, 89%), softenes at 
80-82C. IR (ATR): 3234m, 3060w, 2934m, 2816m, 1610w, 1578s, 
1538m, 1489w, 1463w, 1447w, 1433w, 1403w, 1368m, 1331m, 
1283w, 1255w, 1201w, 1136m, 1112w, 1080w, 1033w, 999w, 904w, 
878w, 854w, 819w, 806w, 764w, 730w, 649w, 621w, 598w, 539w, 
494w, 430w cm-1. 1H NMR (200 MHz, CDCl3/CD3OD): 8.40 (d, 1H, 
J = 5.6 Hz, H-C(2)), 8.00-7.80 (m, 2H, H-C(8), H-C(5)), 7.50-7.40 (br 
s, 1H, -NH), 7.29 (dd, 1H, J = 2.4 Hz, J = 9.0 Hz, H-C(6)), 6.30 (d, 
1H, J = 5.6 Hz, H-C(3)), 3.50-3.20 (m, 2H, ArNHCH2-), 3.10-2.90 (m, 2H, -CH2NH2), 2.90-2.40 
(s, 12H, -CH2N(CH2CH2)2NCH2-, -N(CH2CH2)2N-), 2.10-1.80 (m, 2H, ArNHCH2CH2-), 1.80-
1.60 (m, 2H, -CH2CH2NH2). 13C NMR (50 MHz, CDCl3/CD3OD): 151.40; 150.63; 148.28; 
134.63; 127.43; 124.52; 122.30; 117.13; 98.16; 57.56; 56.24; 52.93; 43.06; 40.00; 29.35; 23.34. 
HRMS: m/z 362.20995 corresponds to molecular formula C19H28ClN5H+ (error in ppm -1.80).  
 
NCl
NH
N
N
NH2
S23 
 
N-{3-[4-(3-{[2-(1-Adamantyl)ethyl]amino}propyl)piperazin-1-yl]propyl}-7-chloroquinolin-
4-amine (38). 
Compound 38 was prepared from amine 37 (137 mg, 0.38 
mmol) and adamantane-1-acetaldehyde (68 mg, 0.38 mmol) 
using NaBH(OAc)3 (161 mg, 0.76 mmol) by procedure D 
and was obtained after dry-flash chromatography (SiO2, 
eluent: DCM/MeOH(NH3 satd) = 100/2) and flash 
chromatography (Biotage SP1 RP column, gradient: 
MeOH/H2O = 8/1→95/5) as a colorless foam (108 mg, 
54%) softenes at 120-122 °C. IR (ATR): 3235m, 2899s, 
2841m, 2806m, 1610w, 1586s, 1540m, 1486w, 1446m, 
1368w, 1353w, 1332w, 1307w, 1283w, 1242w, 1198w, 
1140m, 1074w, 1016w, 987m, 958m, 898w, 875w, 856w, 836w, 812m, 793, 759w, 728m, 596m, 
501m, 428w cm-1. 1H NMR (200 MHz, CDCl3): 8.50 (d, 1H, J = 5.0 Hz, H-C(2)), 8.00-7.80 (m, 
2H, H-C(8), H-C(5)), 7.58 (br s, 1H, -NH), 7.30 (dd, 1H, J = 1.9 Hz, J = 9.0 Hz, H-C(6)), 6.30 
(d, 1H, J = 5.6 Hz, H-C(3)), 3.45-3.25 (m, 2H, ArNHCH2-), 3,00-2,20 (m, 16H, -
CH2NHCH2CH2Ad, -CH2CH2Ad, -N(CH2CH2)2N-, -CH2 N(CH2CH2)2NCH2-), 2.10-1.40 (m, 
19H, ArNHCH2CH2-, -CH2CH2NHCH2CH2Ad, -Ad), 1.40-1.35 (m, 2H, -CH2Ad). 13C NMR (50 
MHz, CDCl3): 152.12; 150.54; 148.99; 134.54; 128.44; 124.54; 122.43; 117.40; 98.38; 58.74; 
57.25; 53.46; 53.28; 48.72; 44.17; 42.50; 37.00; 31.76; 28.51; 26.51; 23.27. Anal. (C31H46ClN5 × 
3/2H2O) Calcd: C, 67.55; H, 8.96; N, 12.71. Found: C, 67.86; H, 9.22; N, 12.89.  
 
N-(prop-2-yn-1-yl)-N'-(quinolin-4-yl)butane-1,4-diamine (41). 
According to the procedure described in literature12, AQ87 (203.6 
mg, 0.9457 mmol) was dissolved in EtOHaps (10 mL), K2CO3 was 
added (130.7 mg, 0.9457 mmol), and then propargyl bromide (36 μL, 
0.47 mmol). The mixture was stirred at r.t. for 24 h. Solvent was 
evaporated under the reduced pressure, and crude product was purified using column 
chromatography (dry-flash, SiO2, eluent DCM, DCM/MeOH gradient 7/3 → 3/7). Final product 
41 was obtained as colorless oil (59 mg, 49%). IR (ATR): 3287m, 3066m, 2931m, 2856m, 
1617w, 1579s, 1540m, 1457w, 1438w, 1395w, 1373w, 1339m, 1281w, 1251w, 1225w, 1170w, 
N
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1127w, 1036w, 867w, 808w, 763m, 651w cm-1. 1H NMR (200 MHz, CDCl3, δ): 8.54 (d, J = 5.6, 
H-C(2)), 8.01-7.93 (m, H-C(8)), 7.82-7.75 (m, H-C(5)), 7.66-7.55 (m, H-C(7)), 7.45-7.34 (m, H-
C(6)), 6.38 (d, J = 5.6, H-C(3)), 5.88-5.74 (m, H-N), 3.46-3.43 (m, 2H, -CH2C≡CH), 3.36-3.23 
(m, 2H, ArNHCH2-), 2.82-2.72 (m, 2H, ArNHCH2CH2CH2CH2-), 2.27-2.20 (m, 1H, -C≡CH), 
1.93-1.77 (m, 2H, ArNHCH2CH2-), 1.75-1.59 (m, 2H, ArNHCH2CH2CH2-). 13C NMR (50 MHz, 
CDCl3, δ): 151.01, 149.85, 148.37, 129.74, 128.85, 124.37, 119.64, 118.80, 98.50, 81.82, 71.50, 
47.85, 43.01, 38.05, 27.39, 26.24. HRMS: m/z 254.16429 corresponds to molecular formula 
C16H19N3H+ (error in ppm -3.47). 
 
N-(7-chloroquinolin-4-yl)acetamide (42).10 
A solution of S2 (844 mg, 4.73 mmol) in acetic anhydride (3.4 mL) was 
refluxed for 2h. After cooling to r.t. brine and 10% aqueous NaOH were added. 
The mixture was extracted with ethyl acetate and organic extracts were dried 
over anh. Na2SO4. The product was purified using column chromatography 
(dry-flash, SiO2, eluent EtOAc/MeOH and flash, Biotage SP1, RP column, 
eluent MeOH/H2O). Final product 42 was obtained as white solid (799 mg, 91 %). M.p. = 169 – 
172 ºC. IR (KBr): 3434s, 3267s, 3048m, 2924m, 2852m, 1662s, 1614s, 1594m, 1570s, 1528s, 
1491s, 1444m, 1422m, 1384m, 1371m, 1311s, 1274m, 1244m, 1187w, 1167w, 1104w, 1081w, 
1041w, 1016w, 959w, 970w, 918w, 854m, 833m, 818m, 765w, 714m, 668w, 636w, 615w, 
587w, 557w, 519w, 502w, 474w, 433w, 420w, 403w cm-1. 1H NMR (500 MHz, CD3OD, δ): 
8.79-8.68 (m, H-C(2)), 8.26-8.19 (m, H-C(5)), 8.18-8.11 (m, H-C(8)), 8.30-7.92 (m, H-C(3)), 
2.33 (s, 3H, CH3-). 13C NMR (125 MHz, CD3OD, δ): 172.74, 153.10, 150.25, 144.14, 137.05, 
128.55, 128.39, 124.95, 121.12, 113.90, 24.30. HRMS: m/z 221.04691 corresponds to molecular 
formula C11H9ClN2OH+ (error in ppm -3.19). 
 
N-(5,6,7,8-tetrahydroquinolin-4-yl)acetamide (43). 
Compound 42 (551 mg, 2.49 mmol) was hydrogenated using PtO2 (55 mg, 10 wt. 
%) as catalyst under hydrogen (50 psi) in glac. AcOH (48 mL) and perchloric acid 
(0.3 mL). The mixture was shaken at r.t. for 64 h. The catalyst was filtered off, 10% 
NaOH in water was added to filtrate, extracted with DCM and dried over anh. 
Na2SO4. The product was purified using column chromatography (dry-flash, SiO2, eluent 
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EtOAc/MeOH). Final product 43 was obtained as white solid (310 mg, 65 %). M.p. = 148 – 151 
ºC. IR (ATR): 3352m, 3147m, 3069m, 2934s, 2860m, 1702s, 1682s, 1583s, 1514s, 1459m, 
1435m, 1406m, 1369m, 1337m, 1297s, 1254m, 1166w, 1002w, 845w, 736w cm-1. 1H NMR (500 
MHz, CD3OD, δ): 8.17 (d, J = 5.5, H-C(2)), 7.72 (d, J = 5.5, H-C(3)), 2.92-2.82 (m, 2H, H-
C(8)), 2.72-2.65 (m, 2H, H-C(5)), 2.20 (s, 3H, CH3), 1.91-1.79 (m, 4H, H-C(6) and H-C(7)). 13C 
NMR (125 MHz, CD3OD, δ): 172.45, 158.64, 146.69, 146.37, 125.22, 116.29, 33.14, 24.81, 
24.00, 23.47, 23.41. HRMS: m/z 191.11758 corresponds to molecular formula C11H14N2OH+ 
(error in ppm -1.64). 
 
5,6,7,8-Tetrahydroquinolin-4-amine (44). 
The solution of 43 in 2M HCl was stirred for 3 h at 70 °C. After cooling to r. t., 
ammonia was added. The mixture was extracted with DCM and dried over anh. 
Na2SO4. Final product 44 was obtained after evaporation of organic layer as pale 
yellow solid (182 mg, 89 %). M.p. = 125 – 126 ºC. IR (ATR): 3336s, 3194s, 2933s, 2860m, 
1637s, 1590s, 1481m, 1451m, 1351m, 1274w, 1190w, 1164w, 1102w, 899w, 818m, 736 cm-1. 
1H NMR (500 MHz, CDCl3, δ): 8.02 (d, J = 5.5, H-C(2)), 6.38 (d, J = 5.5, H-C(3)), 4.05 (bs, 
NH2), 2.95-2.73 (m, 2H, H-C(5)), 2.59-2.33 (m, 2H, H-C(8)), 2.10-1.76 (m, 4H, H-C(6) and H-
C(7)). 13C NMR (125 MHz, CDCl3, δ): 157.03, 150.83, 146.74, 115.84, 107.10, 32.71, 22.87, 
22.75, 22.48. HRMS: m/z 149.10661 corresponds to molecular formula C9H12N2H+ (error in ppm 
-4.78). 
 
4-Chloro-5,6,7,8-tetrahydroquinoline (45). 
To a stirring solution of 44 (380 mg, 2.6 mmol) in glac. AcOH (2.3 mL) at 0 °C, 
28% HCl (1.5 mL) and aqueous solution of NaNO2 (257 mg, 0.85 mL) were added 
dropwise, respectively. After 10 minutes at 0 °C, resulting mixture was added 
dropwise to a solution of CuCl (659 mg, 6.66 mmol) in 28 % HCl (1.2 mL) at same temperature. 
The stirring was continued at r. t. After 17 h, solution of NaOH in water was added and extracted 
with DCM. Organic layer was dried over anh. Na2SO4. The crude product was purified using 
colum chromatography (dry-flash, SiO2, eluent EtOAc/MeOH). Final product 45 was obtained as 
a coroless oil (226 mg, 53%). IR (ATR): 3041w, 2937s, 2863s, 1734w, 1674w, 1553s, 1451s, 
1432m, 1400s, 1332w, 1230w, 1194w, 1161w, 1082w, 1061w, 953w, 834m, 787m, 672w cm-1. 
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1H NMR (500 MHz, CDCl3, δ): 7,77-7,65 (m, H-C(2)), 7,58-7,48 (m, H-C(3)), 1,88-1,20 (m, 8H, 
H-C(5), H-C(6), H-C(7) and H-C(8)). GC/MS (m/z (%)): 165.9 ([M+], 100); 132.0 (33). 
 
N1-(5,6,7,8-tetrahydroquinolin-4-yl)octane-1,8-diamine (46). 
Compound 46 was prepared by procedure E, using Pd(OAc)2 
(9.9 mg, 0.044 mmol), SPhos (36.3 mg, 0.0883 mmol), 45 (185 
mg, 1.10 mmol), 1,8-diaminooctane (239 mg, 1.66 mmol), 
K3PO4 (587 mg, 2.76 mmol) and dioxane (9.3 mL). Final 
product 46 was obtained as colorless oil (200 mg, 66%). IR (ATR): 3299m, 2928s, 2855s, 1592s, 
1523m, 1456m, 1344m, 1165w, 808 cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.08 (d, J = 5.7, H-
C(2)), 6.31 (d, J = 5.7, H-C(3)), 3.93 (s, H-N, exchangable with D2O), 3.25 – 3.05 (m, 2H), 2.90 
– 2.75 (m, 2H), 2.68 (t, J = 7.0, 2H), 2.41 – 2.26 (m, 2H), 1.94 – 1.76 (m, 4H), 1.74 – 1.54 (m, 
4H), 1.50 – 1.25 (m, 8H). 13C NMR (125 MHz, CDCl3, δ): 155.72, 151.44, 147.10, 114.97, 
102.21, 42.95, 42.19, 33.75, 32.71, 29.37, 29.31, 29.21, 26.99, 26.79, 22.70, 22.64, 22.50. 
HRMS: m/z 276.24282 corresponds to molecular formula C17H29N3H+ (error in ppm -2.19). 
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Table S1. In vitro activities against L. infantum and L. tropica promastigotes and cytotoxicity 
against THP-1 human cellsa 
 
Comp. 
L.  
infantum IC50 
(µM)b 
L. 
 tropica IC50 
(µM)b 
THP-1 
IC50 (µM)c 
SI 
(THP/  L.i.)d 
SI 
(THP/ L.t.)d 
Ref. of 
comp.e 
1 8.67 2.77 23.66 2.7 8.5 new 
2 6.49 2.96 >109.6 >16.9 >37.0 new 
3 16.60 9.35 >65.2 >3.9 >7.0 new 
4 16.60 6.63 >59.7 >3.6 >9.0 new 
5 1.91 2.24 12.59 6.6 5.6 new 
6 1.77 1.30 6.39 3.6 4.9 new 
7 0.73 0.66 1.81 2.5 2.7 14 
8 2.46 1.84 3.29 1.3 1.8 14 
9 2.40 2.35 4.90 2.0 2.1 14 
10 0.52 0.51 1.00 1.9 2.0 new 
11 1.14 1.31 2.96 2.6 2.3 7 
12 0.64 0.68 3.76 5.8 5.5 7 
13 1.23 1.24 4.25 3.4 3.4 7 
14 0.51 0.50 1.91 3.8 3.8 7 
15 0.48 0.43 4.73 9.9 10.9 new 
16 1.03 0.81 2.31 2.2 2.8 11 
17 1.02 0.85 4.28 4.2 5.0 13 
18 1.24 1.02 2.35 1.9 2.3 15 
19 0.98 0.91 2.44 2.5 2.7 11 
20 1.55 1.22 2.79 1.8 2.3 11 
21 1.02 1.37 7.11 7.0 5.2 new 
22 >76.5 >76.5 >76.5 >1 >1 new 
23 >69.1 >69.1 >69.1 >1 >1 new 
24 0.72 0.75 2.31 3.2 3.1 new 
25 0.83 0.80 3.68 4.4 4.6 new 
26 2.30 1.94 5.01 2.2 2.6 11 
27 1.22 1.54 2.80 2.3 1.8 11 
28 5.42 7.11 8.10 1.5 1.1 11 
29 0.35 0.30 1.38 4.0 4.6 11 
30 0.80 1.06 3.85 4.8 3.6 11 
Controlf 0.13 0.14 >10.8 >83.1 >77.1 / 
aAntileishmanial IC50 values against promastigote stages (μM), MTT assay; bAll in vitro experiments 
were performed in duplicate, mean values are given; cCytotoxicity against differentiated THP-1, 
human monocytic cell line derived from an acute monocytic leukemia patient. dSelectivity index; eThe 
syntheses of compounds are presented in our previous papers7,11,13,14,15. fControl drug: amphotericin B 
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Table S2. In vitro activities against intramacrophage L. infantum amastigotes 
 
Compound 
In Vitro 
Antiamastigote 
Activity 
at 0.5 µMa 
In Vitro 
Antiamastigote 
Activity 
IC50 (µM),b 
THP-1c 
IC50 (µM) 
SI 
(THP/IPT)d 
1 8.9  23.7  
2 0.2  >109.6  
3 18.3  >65.2  
4 0  >59.7  
5 13.9  12.6  
6 23.3  6.40  
7 15.8  1.80  
8 29.6 1.91 3.29 1.72 
9 22  4.90  
10 72.2 0.31 1.00 3.22 
11 26.4 1.85 2.96 1.60 
12 0  3.76  
13 38.9 1.29 4.25 3.29 
14 26.4 >1 1.91 < 1.91 
15 47.6 0.58 4.73 8.15 
16 10.4  2.31  
17 14.4  4.28  
18 42.7 0.65 2.35 3.61 
19 36.9 0.73 2.44 3.34 
20 42.2 0.79 2.79 3.51 
21 21  7.11  
22 1.1  >76.5  
23 11.8  >69.1  
24 29.6 >1 2.31 < 2.3 
25 20.5  3.68  
26 2.4  5.01  
27 12.7  2.80  
28 13.8  8.10  
29 13.5  1.38  
30 23.6  3.85  
Controle 95.5 0.21 >10.8 >51.4 
aMean value of two or three experiments. bMean value of two experiments. cCytotoxicity against 
differentiated THP-1, human monocytic cell line derived from an acute monocytic leukemia patient. 
dSelectivity Index (IC50 against THP-1/IC50 against intracellular amastigotes); eControl drug: 
amphotericin B. 
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Table S3. Antileishmanial activity in vivo. 
Control (PBS) Liver weight in mg (W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 930 40/503  74.0 
2 1000 44/502 87.6 
3 700 49/507 67.6 
4 630 35/506 43.6 
5 622 47/500 58.5 
Mean      66.3 
Comp. 10 
(100mg/kg × 4 days, p.o.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 672 0/500 0 
2 636 0/500 0 
3 798 0/500 0 
Mean     0 
Reduction from control (%)     100 
Note: signs of toxicity; 1 mouse died on D10; 1 mouse died on D12  
Comp. 10 
 (60mg/kg × 4 days, p.o.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 655 2/505 2.6 
2 482 2/500 1.9 
3 653 3/507 3.9 
4 753 1/500 1.5 
5 756 2/503 3.0 
Mean     2.6 
Reduction from control (%)     96.1 
Comp. 10 
 (10mg/kg × 4 days, s.c.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 575 10/500 11.5 
2 544 12/510 12.8 
3 666 12/507 15.7 
4 528 9/500 9.5 
5 609 10/508 12.0 
Mean     12.3 
Reduction from control (%)     81.4 
Comp. 15 
 (100mg/kg × 4 days, p.o.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 638 1/500 1.3 
2 630 2/503 2.5 
3 747 0/500 0 
4 830 0/508 0 
5 513 0/503 0 
Mean     0.76 
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Reduction from control (%)     98.8 
Comp. 15 
 (50mg/kg × 4 days, p.o.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load        
W x A/C 
1 838 2/506 3.3 
2 730 2/510 2.9 
3 695 3/500 4.2 
4 725 2/502 2.9 
5 572 3/503 3.4 
Mean     3.3 
Reduction from control (%)     95.0 
 
Table S4. Antileishmanial activity in vivo. 
Control (PBS) Liver weight in mg (W) 
Amastigotes/Liver cell 
(A/C) 
Relative load          
W x A/C 
1 720 50/503 71.6 
2 820 56/500 91.8 
3 950 48/513 90.7 
4 570 50/548 52.0 
5 510 46/500 46.9 
Mean relative load      70.6 
Comp. 10 
 (5mg/kg × 5 days, s.c.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load          
W x A/C 
1 680 24/500 32.6 
2 780 20/510 30.6 
3 750 18/500 27.0 
4 720 25/500 36.0 
5 600 22/515 25.6 
Mean relative load     30.4 
Reduction from control (%)     56.9 
Comp. 15 
 (10mg/kg × 5 days, s.c.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load          
W x A/C 
1 920 22/500 40.5 
2 720 23/510 32.5 
3 810 23/500 37.3 
4 890 21/520 35.9 
5 740 25/515 35.9 
Mean relative load     36.4 
Reduction from control (%)     48.4 
Comp. 15 
 (5mg/kg × 5 days, s.c.) 
Liver weight in mg 
(W) 
Amastigotes/Liver cell 
(A/C) 
Relative load          
W x A/C 
1 1080 28/500 60.5 
2 830 30/510 48.8 
3 680 38/500 51.7 
 Me
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